Skip to Content

Tyzeka Novartis - Treatment for Chronic Hepatitis B

Tyzeka is a synthetic thymidine nucleoside analogue indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Related Articles:

Tyzeka (telbivudine) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.